These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1845094)

  • 1. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
    Poewe WH; Lees AJ; Stern GM
    Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating motor fluctuations with controlled-release levodopa preparations.
    Koller WC; Pahwa R
    Neurology; 1994 Jul; 44(7 Suppl 6):S23-8. PubMed ID: 8047257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
    Rondot P; Ziegler M; Aymard N; Holzer J
    Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
    Chouza C; Aljanati R; Caamaño JL; De Medina O; Scaramelli A; Buzó R; Plachín V; Fernandez A; Romero S
    Adv Neurol; 1990; 53():519-26. PubMed ID: 2122654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
    De Michele G; Mengano A; Filla A; Trombetta L; Campanella G
    Acta Neurol (Napoli); 1989 Dec; 11(6):408-14. PubMed ID: 2694799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
    Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN
    Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.